preferences. The voting panel cautioned that many patients treated with certain monoclonal antibodies may require ongoing treatment with methotrexate to prevent the formation of antidrug antibodies Recommendations for specific patient populations (Table 6) Subcutaneous nodules Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-tohigh disease activity Switching to a non-methotrexate DMARD is conditionally recommended over